<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02341066</url>
  </required_header>
  <id_info>
    <org_study_id>H89D14000850003</org_study_id>
    <secondary_id>GR-2011-02352816</secondary_id>
    <nct_id>NCT02341066</nct_id>
  </id_info>
  <brief_title>Endothelial Dysfunction Evaluation for Coronary Heart Disease Risk Estimation in Rheumatoid Arthritis (EDRA Study)</brief_title>
  <acronym>EDRA</acronym>
  <official_title>Evaluation of a New Score Incorporating Endothelial Dysfunction for the Assessment of Coronary Heart Disease Risk in Patients With Rheumatoid Arthritis: a 3-year Prospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero Universitaria di Sassari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliero Universitaria di Cagliari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Complesso Integrato Columbus, Roma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliero Universitaria di Sassari</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the contribution of the assessment of endothelial dysfunction (ED) in improving
      coronary hearth disease (CHD) risk stratification obtained by the Framingham risk score (FRS)
      in rheumatoid arthritis population (RA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ED, determined by peripheral arterial tonometry (PAT), will be evaluated at baseline in 3000
      RA patients free of previous cardiovascular events. Incident CHD events during the 3-year
      planned follow-up will be registered. A measure of the incremental yield of ED will be
      obtained comparing 2-year Framingham risk score for CHD (FRS) and FRS plus ED differential
      prognostic performances by C-statics and risk reclassification analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CHD events</measure>
    <time_frame>3 year</time_frame>
    <description>The following events will be considered as incident CHD events: myocardial infarction, CHD death, resuscitated cardiac arrest, or definite or probable angina if followed by coronary revascularization.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Rheumatoid Arthritis</arm_group_label>
    <description>Rheumatoid arthritis patients free of overt cardiovascular disease. Endothelial Dysfunction evaluation by EndoPAT</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endothelial Dysfunction evaluation by EndoPAT</intervention_name>
    <description>Endothelial dysfunction will be measured assessing reactive hyperemia of digital arteries by using Endo-PAT2000 (Itamar, Israel).</description>
    <arm_group_label>Rheumatoid Arthritis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Three thousand consecutive RA patients free of overt cardiovascular disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RA as defined by American College of Rheumatology/European League Against Rheumatisms
             2010 RA classification criteria

          -  In the opinion of investigators, patients must be able to adhere to the study visit
             schedule and must be capable of giving informed consent

        Exclusion Criteria:

          -  Previous cardiovascular or cerebrovascular events (acute coronary syndrome, stable
             angina, stroke, interventional procedures, carotid endarterectomy, symptomatic
             peripheral artery ischemia)

          -  Pathological ECG at rest

          -  Sign or symptoms of autonomous nervous system dysfunction

          -  Serious infections in the previous 6 months

          -  Concomitant severe illness: overt hepatic insufficiency; End stage renal disease
             (Glomerular Filtration Rate &lt;30 ml/h at Cockrofts-Gault formula); recent diagnosis of
             cancer

          -  Pregnancy

          -  Plans to leave target areas of each study site within three years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gian Luca Erre, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero Universitaria di Sassari</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gian Luca Erre, MD, PhD</last_name>
    <phone>+39079228448</phone>
    <email>e.gianluca@libero.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Policlinico Universitario di Monserrato Azienda Ospedaliera Universitaria di Cagliari</name>
      <address>
        <city>Monserrato</city>
        <state>Cagliari</state>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matteo Piga, MD</last_name>
      <phone>+3907051096142</phone>
      <email>matteopiga@alice.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complesso Integrato Columbus, UO di Reumatologia</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Laura Fedele, MD</last_name>
    </contact>
    <contact_backup>
      <phone>+39063503731</phone>
      <email>annalaurafedele@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Sassari, UOC di Reumatologia</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gian Luca Erre, MD, PhD</last_name>
      <phone>+39079228448</phone>
      <email>e.gianluca@libero.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, Hartz SC. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000 Feb;139(2 Pt 1):272-81. Erratum in: Am Heart J 2002 Jan;143(1):21.</citation>
    <PMID>10650300</PMID>
  </reference>
  <reference>
    <citation>Crowson CS, Matteson EL, Roger VL, Therneau TM, Gabriel SE. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol. 2012 Aug 1;110(3):420-4. doi: 10.1016/j.amjcard.2012.03.044. Epub 2012 Apr 20.</citation>
    <PMID>22521305</PMID>
  </reference>
  <reference>
    <citation>Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004 Dec 7;44(11):2137-41.</citation>
    <PMID>15582310</PMID>
  </reference>
  <reference>
    <citation>Matsuzawa Y, Sugiyama S, Sugamura K, Nozaki T, Ohba K, Konishi M, Matsubara J, Sumida H, Kaikita K, Kojima S, Nagayoshi Y, Yamamuro M, Izumiya Y, Iwashita S, Matsui K, Jinnouchi H, Kimura K, Umemura S, Ogawa H. Digital assessment of endothelial function and ischemic heart disease in women. J Am Coll Cardiol. 2010 Apr 20;55(16):1688-96. doi: 10.1016/j.jacc.2009.10.073.</citation>
    <PMID>20394872</PMID>
  </reference>
  <reference>
    <citation>Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, Pumper GM, Lerman LO, Lerman A. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J. 2010 May;31(9):1142-8. doi: 10.1093/eurheartj/ehq010. Epub 2010 Feb 24.</citation>
    <PMID>20181680</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2015</study_first_submitted>
  <study_first_submitted_qc>January 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <last_update_submitted>February 25, 2016</last_update_submitted>
  <last_update_submitted_qc>February 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero Universitaria di Sassari</investigator_affiliation>
    <investigator_full_name>Gian Luca Erre, MD PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Cardiovascular risk score</keyword>
  <keyword>Framingham risk score 2-year</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <keyword>EndoPAT</keyword>
  <keyword>Rheumatoid arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

